▼ -11.05% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $7.13, with a high forecast of $12.50 and a low forecast of $3.00. The average price target represents a -11.05% upside from the last price of $8.01.
The current consensus among 4 polled investment analysts is to buy stock in Solid Biosciences. This rating has held steady since July 2020, when it changed from a Hold consensus rating.
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.